Adjuvant immunochemotherapy with protein-bound polysaccharide K for colon cancer in relation to oncogenic β-catenin activation

Kaname Yamashita, Andrei V. Ougolkov, Hiroaki Nakazato, Katsuki Ito, Yasuo Ohashi, Hidekazu Kitakata, Kazuo Yasumoto, Kazuhiko Omote, Masayoshi Mai, Yutaka Takahashi, Toshinari Minamoto*

*Corresponding author for this work

Research output: Contribution to journalArticle

11 Scopus citations

Abstract

PURPOSE: Protein-bound polysaccharide K is an immunotherapeutic agent that promotes apoptosis by inhibiting nuclear factor-kappaB activation in cancer cells. We previously showed that oncogenic β-catenin activates nuclear factor-kappaB and inhibits apoptosis by up-regulating β-transducin repeat-containing protein. We investigated whether the activation state of β-catenin in the primary tumor is associated with differences in survival rates of patients with colon cancer undergoing immunochemotherapy with 5-fluorouracil plus polysaccharide K vs. chemotherapy with 5-fluorouracil alone. METHODS: We assessed the activation states of β-catenin and nuclear factor-kappaB in the primary tumors of 202 colon cancer patients, and analyzed the data in terms of the clinicopathologic characteristics and survival of patients undergoing the two forms of adjuvant therapy. RESULTS: We found two distinct patterns of nuclear accumulation of activated β-catenin in the tumor cells: diffuse nuclear accumulation in 89 cases (44 percent) and selective nuclear accumulation at the tumor invasion front in 18 cases (9 percent). Nuclear factor-kappaB activation was found in 64 cases (32 percent). In patients with diffuse nuclear accumulation-type β-catenin activation, immunochemotherapy significantly improved recurrence-free survival, cancer death survival, and overall survival rates compared with patients receiving chemotherapy alone. No survival benefit was found in cases with nuclear accumulation at the tumor invasion front-type β-catenin activation or no activation. Similarly, immunochemotherapy favored the survival of patients with nuclear factor-kappaB activation. Multivariate analysis established the TNM stage and administration of polysaccharide K as independent prognostic factors in the patients with diffuse nuclear accumulation-type β-catenin activation. CONCLUSIONS: The presence of diffuse nuclear accumulation-type β-catenin activation identifies patients with colon cancer who respond better to immunotherapy with polysaccharide K.

Original languageEnglish (US)
Pages (from-to)1169-1181
Number of pages13
JournalDiseases of the colon and rectum
Volume50
Issue number8
DOIs
StatePublished - Aug 2007

Keywords

  • Colon cancer
  • Immunochemotherapy
  • Nuclear factor-kappaB
  • Protein-bound polysaccharide K
  • β-catenin

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint Dive into the research topics of 'Adjuvant immunochemotherapy with protein-bound polysaccharide K for colon cancer in relation to oncogenic β-catenin activation'. Together they form a unique fingerprint.

  • Cite this

    Yamashita, K., Ougolkov, A. V., Nakazato, H., Ito, K., Ohashi, Y., Kitakata, H., Yasumoto, K., Omote, K., Mai, M., Takahashi, Y., & Minamoto, T. (2007). Adjuvant immunochemotherapy with protein-bound polysaccharide K for colon cancer in relation to oncogenic β-catenin activation. Diseases of the colon and rectum, 50(8), 1169-1181. https://doi.org/10.1007/s10350-006-0842-5